A Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer

Cancer Cell

Volumn 27, Issue 2, 2015, Pages 223-239

  Vidal, SamuelJ ^a,b   Rodriguez Bravo, Veronica ^c   Quinn, S Aidan ^d   Rodriguez Barrueco, Ruth ^b   Lujambio, Amaia ^c   Williams, Estrelania ^b   Sun, Xiaochen ^b   delaIglesia Vicente, Janis ^b   Lee, Albert ^e   Readhead, Ben ^b   Chen, Xintong ^b   Galsky, Matthew ^b   Esteve, Berta ^b   Petrylak, DanielP ^f   Dudley, JoelT ^b   Rabadan, Raul ^e   Silva, JoseM ^b   Hoshida, Yujin ^b   Lowe, ScottW ^c   Cordon Cardo, Carlos ^b   Domingo Domenech, Josep ^b   more..

^a Columbia University ^*  (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d NewYork Presbyterian Hospital   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

^f YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CABAZITAXEL; DOCETAXEL; LINSITINIB; SOMATOMEDIN B; TRANSCRIPTION FACTOR GATA 2; GATA2 PROTEIN, HUMAN; IGF2 PROTEIN, HUMAN; INSR PROTEIN, HUMAN; INSULIN RECEPTOR; LEUKOCYTE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENICITY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; CLINICAL STUDY; CONTROLLED STUDY; DATA BASE; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SCREENING; GENETICS; MOUSE; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANIMALS; ANTIGENS, CD; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; GATA2 TRANSCRIPTION FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MICE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922788911     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.11.013     Document Type: Article

References (51)

1. Bates P., Fisher R., Ward A., Richardson L., Hill D.J., Graham C.F. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br. J. Cancer 1995, 72:1189-1193.
2. Beer T.M., Armstrong A.J., Rathkopf D.E., Loriot Y., Sternberg C.N., Higano C.S., Iversen P., Bhattacharya S., Carles J., Chowdhury S., et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N.Engl. J. Med. 2014, 371:424-433.
3. Bishr M., Saad F. Overview of the latest treatments for castration-resistant prostate cancer. Nat. Rev. Urol. 2013, 10:522-528.
4. Buck E., Gokhale P.C., Koujak S., Brown E., Eyzaguirre A., Tao N., Rosenfeld-Franklin M., Lerner L., Chiu M.I., Wild R., et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol. Cancer Ther. 2010, 9:2652-2664.
5. Chen L., Mooso B.A., Jathal M.K., Madhav A., Johnson S.D., van Spyk E., Mikhailova M., Zierenberg-Ripoll A., Xue L., Vinall R.L., et al. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3. Clin. Cancer Res. 2011, 17:6218-6228.
6. Chen Y., Chi P., Rockowitz S., Iaquinta P.J., Shamu T., Shukla S., Gao D., Sirota I., Carver B.S., Wongvipat J., et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat. Med. 2013, 19:1023-1029.
7. Chiang Y.T., Wang K., Fazli L., Qi R.Z., Gleave M.E., Collins C.C., Gout P.W., Wang Y. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget 2014, 5:451-461.
8. Christofori G., Naik P., Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994, 369:414-418.
9. Church D.N., Phillips B.R., Stuckey D.J., Barnes D.J., Buffa F.M., Manek S., Clarke K., Harris A.L., Carter E.J., Hassan A.B. Igf2 ligand dependency of Pten(+/-) developmental and tumour phenotypes in the mouse. Oncogene 2012, 31:3635-3646.
10. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., Gravis G., Bodrogi I., Mackenzie M.J., Shen L., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154. TROPIC Investigators.
11. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B., Saad F., et al. Abiraterone and increased survival in metastatic prostate cancer. N.Engl. J. Med. 2011, 364:1995-2005. COU-AA-301 Investigators.
12. de Bono J.S., Piulats J.M., Pandha H.S., Petrylak D.P., Saad F., Aparicio L.M., Sandhu S.K., Fong P., Gillessen S., Hudes G.R., et al. Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2014, 20:1925-1934.
13. Domingo-Domenech J., Vidal S.J., Rodriguez-Bravo V., Castillo-Martin M., Quinn S.A., Rodriguez-Barrueco R., Bonal D.M., Charytonowicz E., Gladoun N., de la Iglesia-Vicente J., et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012, 22:373-388.
14. Drake J.M., Gabriel C.L., Henry M.D. Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin. Exp. Metastasis 2005, 22:674-684.
15. Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat. Rev. Cancer 2004, 4:143-153.
16. Gan Y., Shi C., Inge L., Hibner M., Balducci J., Huang Y. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010, 29:4947-4958.
17. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
18. Hahn H., Wojnowski L., Specht K., Kappler R., Calzada-Wack J., Potter D., Zimmer A., Müller U., Samson E., Quintanilla-Martinez L., Zimmer A. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J.Biol. Chem. 2000, 275:28341-28344.
19. Hahn C.N., Chong C.E., Carmichael C.L., Wilkins E.J., Brautigan P.J., Li X.C., Babic M., Lin M., Carmagnac A., Lee Y.K., et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat. Genet. 2011, 43:1012-1017.
20. Jarrard D.F., Bussemakers M.J., Bova G.S., Isaacs W.B. Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues. Clin. Cancer Res. 1995, 1:1471-1478.
21. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
22. Kumar M.S., Hancock D.C., Molina-Arcas M., Steckel M., East P., Diefenbacher M., Armenteros-Monterroso E., Lassailly F., Matthews N., Nye E., et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 2012, 149:642-655.
23. Liu R., Wang X., Chen G.Y., Dalerba P., Gurney A., Hoey T., Sherlock G., Lewicki J., Shedden K., Clarke M.F. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N.Engl. J. Med. 2007, 356:217-226.
24. Livingstone C. IGF2 and cancer. Endocr. Relat. Cancer 2013, 20:R321-R339.
25. Lubik A.A., Gunter J.H., Hollier B.G., Ettinger S., Fazli L., Stylianou N., Hendy S.C., Adomat H.H., Gleave M.E., Pollak M., et al. IGF2 increases de novo steroidogenesis in prostate cancer cells. Endocr. Relat. Cancer 2013, 20:173-186.
26. Lui J.C., Baron J. Evidence that Igf2 down-regulation in postnatal tissues and up-regulation in malignancies is driven by transcription factor E2f3. Proc. Natl. Acad. Sci. USA 2013, 110:6181-6186.
27. Moorehead R.A., Sanchez O.H., Baldwin R.M., Khokha R. Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 2003, 22:853-857.
28. Mulvihill M.J., Cooke A., Rosenfeld-Franklin M., Buck E., Foreman K., Landfair D., O'Connor M., Pirritt C., Sun Y., Yao Y., et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med. Chem. 2009, 1:1153-1171.
29. Perez-Stable C.M., Pozas A., Roos B.A. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol. Cell. Endocrinol. 2000, 167:43-53.
30. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N.Engl. J. Med. 2004, 351:1513-1520.
31. Pravtcheva D.D., Wise T.L. Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J.Exp. Zool. 1998, 281:43-57.
32. Qiu Y., Ravi L., Kung H.J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature 1998, 393:83-85.
33. Rogler C.E., Yang D., Rossetti L., Donohoe J., Alt E., Chang C.J., Rosenfeld R., Neely K., Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J.Biol. Chem. 1994, 269:13779-13784.
34. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P., Fizazi K., Mainwaring P., Piulats J.M., Ng S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N.Engl. J. Med. 2013, 368:138-148. COU-AA-302 Investigators.
35. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., de Wit R., Mulders P., Chi K.N., Shore N.D., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N.Engl. J. Med. 2012, 367:1187-1197. AFFIRM Investigators.
36. Sharma N.L., Massie C.E., Ramos-Montoya A., Zecchini V., Scott H.E., Lamb A.D., MacArthur S., Stark R., Warren A.Y., Mills I.G., Neal D.E. The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell 2013, 23:35-47.
37. Sramkoski R.M., Pretlow T.G., Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.S., Marengo S.R., Rhim J.S., Zhang D., Jacobberger J.W. A new human prostate carcinoma cell line, 22Rv1. InVitro Cell. Dev. Biol. Anim. 1999, 35:403-409.
38. Stylianopoulou F., Efstratiadis A., Herbert J., Pintar J. Pattern of the insulin-like growth factor II gene expression during rat embryogenesis. Development 1988, 103:497-506.
39. Tada Y., Yamaguchi Y., Kinjo T., Song X., Akagi T., Takamura H., Ohta T., Yokota T., Koide H. The stem cell transcription factor ZFP57 induces IGF2 expression to promote anchorage-independent growth in cancer cells. Oncogene 2014.
40. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Théodore C., James N.D., Turesson I., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N.Engl. J. Med. 2004, 351:1502-1512. TAX 327 Investigators.
41. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., Arora V.K., Kaushik P., Cerami E., Reva B., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
42. Vicente C., Conchillo A., García-Sánchez M.A., Odero M.D. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit. Rev. Oncol. Hematol. 2012, 82:1-17.
43. Vicente C., Vazquez I., Conchillo A., García-Sánchez M.A., Marcotegui N., Fuster O., González M., Calasanz M.J., Lahortiga I., Odero M.D. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia 2012, 26:550-554.
44. Vincent A.M., Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm. IGF Res. 2002, 12:193-197.
45. Vivas-Mejia P., Benito J.M., Fernandez A., Han H.D., Mangala L., Rodriguez-Aguayo C., Chavez-Reyes A., Lin Y.G., Carey M.S., Nick A.M., et al. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin. Cancer Res. 2010, 16:184-194.
46. Wang Q., Li W., Liu X.S., Carroll J.S., Jänne O.A., Keeton E.K., Chinnaiyan A.M., Pienta K.J., Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell 2007, 27:380-392.
47. Wang Q., Li W., Zhang Y., Yuan X., Xu K., Yu J., Chen Z., Beroukhim R., Wang H., Lupien M., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
48. Wang Y., He X., Ngeow J., Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum. Mol. Genet. 2012, 21:569-576.
49. Wu D., Sunkel B., Chen Z., Liu X., Ye Z., Li Q., Grenade C., Ke J., Zhang C., Chen H., et al. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Res. 2014, 42:3607-3622.
50. Yang Y.M., Bost F., Charbono W., Dean N., McKay R., Rhim J.S., Depatie C., Mercola D. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin. Cancer Res. 2003, 9:391-401.
51. Zhang S.J., Ma L.Y., Huang Q.H., Li G., Gu B.W., Gao X.D., Shi J.Y., Wang Y.Y., Gao L., Cai X., et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc. Natl. Acad. Sci. USA 2008, 105:2076-2081.